Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study

Objectives: Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy. This was the first-in-Chinese study aiming to investigate the safety, tolerability, pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xue, Liu, Hongzhong, Tian, Wei, Fang, Ligang, Yu, Mengyang, Wu, Xiaofei, Liu, Aijing, Wan, Ruijie, Li, Li, Luo, Jinghui, Li, Yuqiong, Liu, Bo, He, Yu, Chen, Xiaowen, Li, Yuan, Xu, Donghong, Wang, Hongyun, Han, Xiaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482267/
https://www.ncbi.nlm.nih.gov/pubmed/37680714
http://dx.doi.org/10.3389/fphar.2023.1227470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482267/
https://www.ncbi.nlm.nih.gov/pubmed/37680714
http://dx.doi.org/10.3389/fphar.2023.1227470

Ejemplares similares